KR20220123224A - 로페콕시브의 신규 투여 형태 및 관련 방법 - Google Patents
로페콕시브의 신규 투여 형태 및 관련 방법 Download PDFInfo
- Publication number
- KR20220123224A KR20220123224A KR1020227019672A KR20227019672A KR20220123224A KR 20220123224 A KR20220123224 A KR 20220123224A KR 1020227019672 A KR1020227019672 A KR 1020227019672A KR 20227019672 A KR20227019672 A KR 20227019672A KR 20220123224 A KR20220123224 A KR 20220123224A
- Authority
- KR
- South Korea
- Prior art keywords
- formulation
- rofecoxib
- plasma concentration
- mean
- solid dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 title claims abstract description 956
- 229960000371 rofecoxib Drugs 0.000 title claims abstract description 943
- 238000000034 method Methods 0.000 title claims description 101
- 239000002552 dosage form Substances 0.000 title abstract description 3
- 239000000203 mixture Substances 0.000 claims description 1524
- 238000009472 formulation Methods 0.000 claims description 1512
- 230000036470 plasma concentration Effects 0.000 claims description 469
- 239000007787 solid Substances 0.000 claims description 383
- 208000002193 Pain Diseases 0.000 claims description 64
- 206010061218 Inflammation Diseases 0.000 claims description 62
- 206010037660 Pyrexia Diseases 0.000 claims description 62
- 230000004054 inflammatory process Effects 0.000 claims description 62
- 230000036407 pain Effects 0.000 claims description 62
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 claims description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000005298 acute pain Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 229940087652 vioxx Drugs 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000031209 hemophilic arthropathy Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 235000002639 sodium chloride Nutrition 0.000 description 238
- 239000007884 disintegrant Substances 0.000 description 223
- 150000003839 salts Chemical class 0.000 description 223
- 238000004090 dissolution Methods 0.000 description 125
- 239000008187 granular material Substances 0.000 description 79
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 70
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 70
- 239000011230 binding agent Substances 0.000 description 56
- 239000003085 diluting agent Substances 0.000 description 56
- 239000007909 solid dosage form Substances 0.000 description 54
- 239000003826 tablet Substances 0.000 description 54
- 239000012535 impurity Substances 0.000 description 43
- 239000000314 lubricant Substances 0.000 description 42
- 239000007935 oral tablet Substances 0.000 description 42
- 229940096978 oral tablet Drugs 0.000 description 42
- 235000010980 cellulose Nutrition 0.000 description 35
- 229920002678 cellulose Polymers 0.000 description 35
- 239000001913 cellulose Substances 0.000 description 35
- 239000003086 colorant Substances 0.000 description 29
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 28
- 229920002785 Croscarmellose sodium Polymers 0.000 description 28
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 28
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 229920002472 Starch Polymers 0.000 description 28
- 229960001021 lactose monohydrate Drugs 0.000 description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 28
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 28
- 239000008108 microcrystalline cellulose Substances 0.000 description 28
- 229940016286 microcrystalline cellulose Drugs 0.000 description 28
- 229940032147 starch Drugs 0.000 description 28
- 235000019698 starch Nutrition 0.000 description 28
- 239000008107 starch Substances 0.000 description 28
- 229960001375 lactose Drugs 0.000 description 21
- 239000008101 lactose Substances 0.000 description 21
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 19
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 19
- 239000003937 drug carrier Substances 0.000 description 19
- 239000002245 particle Substances 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 15
- UZLXCHVDUBCZMH-UHFFFAOYSA-N 3-(4-methylsulfanylphenyl)-4-phenyl-2h-furan-5-one Chemical compound C1=CC(SC)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 UZLXCHVDUBCZMH-UHFFFAOYSA-N 0.000 description 14
- 229920002261 Corn starch Polymers 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 14
- 229930006000 Sucrose Natural products 0.000 description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 14
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical group CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 14
- 235000010443 alginic acid Nutrition 0.000 description 14
- 229920000615 alginic acid Polymers 0.000 description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 14
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 14
- 239000004927 clay Substances 0.000 description 14
- 239000008120 corn starch Substances 0.000 description 14
- 229960005168 croscarmellose Drugs 0.000 description 14
- 229960001681 croscarmellose sodium Drugs 0.000 description 14
- 229960000913 crospovidone Drugs 0.000 description 14
- 229920006037 cross link polymer Polymers 0.000 description 14
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 14
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 14
- 229920000591 gum Polymers 0.000 description 14
- 235000019359 magnesium stearate Nutrition 0.000 description 14
- 229920000609 methyl cellulose Polymers 0.000 description 14
- 235000010981 methylcellulose Nutrition 0.000 description 14
- 239000001923 methylcellulose Substances 0.000 description 14
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 14
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 14
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 239000008109 sodium starch glycolate Substances 0.000 description 14
- 229940079832 sodium starch glycolate Drugs 0.000 description 14
- 229920003109 sodium starch glycolate Polymers 0.000 description 14
- 239000005720 sucrose Substances 0.000 description 14
- 235000000346 sugar Nutrition 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- RAECDKKKKNJXTF-UHFFFAOYSA-N 3-(4-methylsulfinylphenyl)-4-phenyl-2h-furan-5-one Chemical compound C1=CC(S(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RAECDKKKKNJXTF-UHFFFAOYSA-N 0.000 description 8
- LJZJWBAPABMSII-UHFFFAOYSA-N 3-(4-methylsulfonylphenyl)-4-phenylfuran-2,5-dione Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1=O LJZJWBAPABMSII-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 244000215068 Acacia senegal Species 0.000 description 7
- 235000006491 Acacia senegal Nutrition 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- 239000005995 Aluminium silicate Substances 0.000 description 7
- 241000416162 Astragalus gummifer Species 0.000 description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 7
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- 229920000084 Gum arabic Polymers 0.000 description 7
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 235000021355 Stearic acid Nutrition 0.000 description 7
- 229920001615 Tragacanth Polymers 0.000 description 7
- 235000010489 acacia gum Nutrition 0.000 description 7
- 235000012211 aluminium silicate Nutrition 0.000 description 7
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 7
- 239000004327 boric acid Substances 0.000 description 7
- 235000010338 boric acid Nutrition 0.000 description 7
- 239000001506 calcium phosphate Substances 0.000 description 7
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 7
- 235000013539 calcium stearate Nutrition 0.000 description 7
- 239000008116 calcium stearate Substances 0.000 description 7
- 229940095672 calcium sulfate Drugs 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 7
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 7
- 239000008121 dextrose Substances 0.000 description 7
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical group [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 7
- 229940038472 dicalcium phosphate Drugs 0.000 description 7
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000010903 husk Substances 0.000 description 7
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 7
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 7
- 229960000367 inositol Drugs 0.000 description 7
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 235000013379 molasses Nutrition 0.000 description 7
- 210000003097 mucus Anatomy 0.000 description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 7
- 239000006186 oral dosage form Substances 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 7
- 239000000600 sorbitol Substances 0.000 description 7
- 239000008117 stearic acid Substances 0.000 description 7
- 239000000454 talc Substances 0.000 description 7
- 229910052623 talc Inorganic materials 0.000 description 7
- 235000012222 talc Nutrition 0.000 description 7
- 235000010487 tragacanth Nutrition 0.000 description 7
- 239000000196 tragacanth Substances 0.000 description 7
- 229940116362 tragacanth Drugs 0.000 description 7
- 239000001993 wax Substances 0.000 description 7
- 230000002411 adverse Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229940041707 rofecoxib 25 mg Drugs 0.000 description 6
- 210000004789 organ system Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 description 1
- 206010003791 Aura Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000012435 analytical chromatography Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- -1 organic acid salts Chemical class 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934898P | 2019-11-13 | 2019-11-13 | |
| US62/934,898 | 2019-11-13 | ||
| US202063018136P | 2020-04-30 | 2020-04-30 | |
| US63/018,136 | 2020-04-30 | ||
| US16/867,514 US10945992B1 (en) | 2019-11-13 | 2020-05-05 | Dosage forms of rofecoxib and related methods |
| US16/867,514 | 2020-05-05 | ||
| PCT/US2020/060152 WO2021097038A1 (en) | 2019-11-13 | 2020-11-12 | Novel dosage forms of rofecoxib and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220123224A true KR20220123224A (ko) | 2022-09-06 |
Family
ID=74870322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227019672A Withdrawn KR20220123224A (ko) | 2019-11-13 | 2020-11-12 | 로페콕시브의 신규 투여 형태 및 관련 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US10945992B1 (enExample) |
| EP (1) | EP4058012A1 (enExample) |
| JP (1) | JP2023502941A (enExample) |
| KR (1) | KR20220123224A (enExample) |
| CN (1) | CN115605197A (enExample) |
| CA (1) | CA3155900A1 (enExample) |
| MX (1) | MX2022005813A (enExample) |
| TW (1) | TW202128144A (enExample) |
| WO (1) | WO2021097038A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7291220B2 (ja) | 2018-11-21 | 2023-06-14 | トレモ― ファーマシューティカルズ，インコーポレーテッド | ロフェコキシブの精製形態、製造方法および使用 |
| US20200323813A1 (en) * | 2019-04-09 | 2020-10-15 | Tremeau Pharmaceuticals, Inc. | Treatment of viral hemorrhagic fevers with cox-2 selective non-steroidal anti-inflammatory drugs |
| US11161833B1 (en) | 2021-04-09 | 2021-11-02 | Tremeau Pharmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture, and use thereof |
| WO2023059698A1 (en) * | 2021-10-06 | 2023-04-13 | Tremeau Pharmaceuticals, Inc. | Methods and compositions for treating von willebrand's migraine disorder |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21647A (en) | 1858-10-05 | Construction of animal-traps | ||
| US21042A (en) | 1858-07-27 | yerby | ||
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| MY119407A (en) | 1993-06-24 | 2005-05-31 | Merck Frosst Canada Inc | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5h)-furanone as a cox-2 inhibitor. |
| CA2180651A1 (en) | 1994-01-10 | 1995-07-13 | Yves Ducharme | Phenyl heterocycles as cox-2 inhibitors |
| US5585504A (en) | 1994-09-16 | 1996-12-17 | Merck & Co., Inc. | Process of making cox-2 inhibitors having a lactone bridge |
| US5849943A (en) | 1994-10-27 | 1998-12-15 | Merck Frosst Canada, Inc. | Stilbene derivatives useful as cyclooxygenase-2 inhibitors |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| BR9709097A (pt) | 1996-05-17 | 1999-08-03 | Merck & Co Inc | Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária |
| GB9615867D0 (en) | 1996-07-03 | 1996-09-11 | Merck & Co Inc | Process of preparing phenyl heterocycles useful as cox-2 inhibitors |
| CN1638739A (zh) | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
| JP4659190B2 (ja) | 2000-08-31 | 2011-03-30 | アンリツ株式会社 | 波形測定装置 |
| US20040186155A1 (en) * | 2003-01-30 | 2004-09-23 | Dayno Jeffrey Marc | Combination therapy for the treatment or prevention of migraine |
| ES2214129B1 (es) | 2003-02-13 | 2005-12-01 | Almirall Prodesfarma, S.A. | 3-fenilfuran-2-onas. |
| EP1646381A4 (en) * | 2003-07-02 | 2009-12-09 | Merck & Co Inc | COMBINATION THERAPY FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES |
| AU2003263582A1 (en) | 2003-08-14 | 2005-03-07 | Shasun Chemicals And Drugs Limited | Process for the manufacture of rofecoxib |
| TR200301552A1 (tr) | 2003-09-18 | 2005-10-21 | Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Rofekoksib' in yeni oral farmakolojik formülasyonları. |
| WO2015066302A2 (en) * | 2013-10-30 | 2015-05-07 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions, methods of use, and methods of treatment |
| CN104173359B (zh) * | 2014-09-05 | 2017-05-03 | 罗国安 | 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用 |
| WO2016089893A1 (en) * | 2014-12-01 | 2016-06-09 | Achelios Therapeutics Inc. | Methods and compositions for treating migraine and conditions associated with pain |
| WO2019193417A1 (en) | 2018-04-05 | 2019-10-10 | Kossen Co., Ltd. | Composition and method of reducing joint pain associated with hemarthrosis |
| JP7291220B2 (ja) * | 2018-11-21 | 2023-06-14 | トレモ― ファーマシューティカルズ，インコーポレーテッド | ロフェコキシブの精製形態、製造方法および使用 |
-
2020
- 2020-05-05 US US16/867,514 patent/US10945992B1/en active Active
- 2020-11-12 KR KR1020227019672A patent/KR20220123224A/ko not_active Withdrawn
- 2020-11-12 WO PCT/US2020/060152 patent/WO2021097038A1/en not_active Ceased
- 2020-11-12 CA CA3155900A patent/CA3155900A1/en active Pending
- 2020-11-12 CN CN202080092241.7A patent/CN115605197A/zh active Pending
- 2020-11-12 TW TW109139523A patent/TW202128144A/zh unknown
- 2020-11-12 EP EP20820012.1A patent/EP4058012A1/en not_active Withdrawn
- 2020-11-12 MX MX2022005813A patent/MX2022005813A/es unknown
- 2020-11-12 JP JP2022528029A patent/JP2023502941A/ja active Pending
- 2020-12-18 US US17/127,970 patent/US20210137878A1/en not_active Abandoned
-
2021
- 2021-02-23 US US17/182,728 patent/US20210169845A1/en not_active Abandoned
- 2021-10-28 US US17/513,281 patent/US20220047542A1/en not_active Abandoned
-
2022
- 2022-06-30 US US17/855,604 patent/US20220409575A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220409575A1 (en) | 2022-12-29 |
| MX2022005813A (es) | 2022-08-16 |
| JP2023502941A (ja) | 2023-01-26 |
| EP4058012A1 (en) | 2022-09-21 |
| WO2021097038A1 (en) | 2021-05-20 |
| TW202128144A (zh) | 2021-08-01 |
| US20210137878A1 (en) | 2021-05-13 |
| CA3155900A1 (en) | 2021-05-20 |
| US10945992B1 (en) | 2021-03-16 |
| US20210169845A1 (en) | 2021-06-10 |
| CN115605197A (zh) | 2023-01-13 |
| US20220047542A1 (en) | 2022-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220409575A1 (en) | Dosage forms of rofecoxib and related methods | |
| RU2640023C2 (ru) | Жидкий состав | |
| AU764742B2 (en) | Dispersible compositions containing L-DOPA ethyl ester | |
| JP2012229275A (ja) | ピルフェニドン療法に付随する有害事象を低減する方法 | |
| JP2025066802A (ja) | ウィルソン病を治療するためのビスコリンテトラチオモリブデート | |
| KR20200059274A (ko) | 케톤 형성 식이 호환성 펜플루라민 제제 | |
| JP2024133735A (ja) | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 | |
| US20240277698A1 (en) | Methods of using aldosterone synthase inhibitors | |
| CN119421712A (zh) | 用于多发性硬化和重症肌无力的治疗性酪氨酸激酶抑制剂 | |
| US12257236B2 (en) | Oral formulations of metronidazole and methods of treating an infection using same | |
| US20210137903A1 (en) | Anti-androgens for the treatment of prostrate cancer | |
| US20250339442A1 (en) | Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor | |
| KR20250024807A (ko) | 플로로글루시놀 제제 및 사용 방법 | |
| TWI243671B (en) | Compositions for treating allergic and inflammatory conditions with cough | |
| ULC | Aldosterone Antagonist | |
| RU2778848C2 (ru) | Состав фенфлурамина, совместимый с кетогенной диетой | |
| JPH1036258A (ja) | 新規な抗痙攣性及び抗炎症性組成物並びにそれらの製造方法 | |
| TW202339727A (zh) | 使用１ｈ－１，２，３－三唑－４－羧酸之治療方法 | |
| JP2026513149A (ja) | 肝障害を有する患者にパルツソチンを投与するための組成物及び方法 | |
| KR20250035000A (ko) | Cyp3a 유도제 및/또는 양성자 펌프 저해제와 조합하여 벨루모수딜을 투여하는 방법 | |
| MXPA00007970A (en) | Compositions and methods for treating allergic and inflammatory conditions with cough |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20220610 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20231128 |
|
| WITB | Written withdrawal of application |